New Delhi, Sept. 9 -- The Indian pharmaceutical industry requires price increases, site and intellectual property (IP) transfers to deal with the prevailing uncertainty in the sector amid US tariffs, according to a report by Systematix Research.

The report highlighted that tariff uncertainty continues to prevail, with companies unwilling to add capacities in the US.

It stated, "Price increase, site and IP transfers are the three tools the industry requires to deal with the tariffs."

At the same time, raw material prices are correcting sharply in certain categories, particularly antibiotics, while customers are destocking to take advantage of lower prices. Overall, generic API prices have stabilized.

The report further noted that compa...